# Retatrutide 20mg

> Triple-agonist — single vial.

Canonical PDP: https://aurex.bio/products/retatrutide-20mg
Research-data API: https://aurex.bio/api/research-data/retatrutide-20mg

## Catalog facts
- Name: Retatrutide
- SKU: `RT20`
- Category: metabolic
- Dosage: 20mg
- Vials per kit: 1
- Total mass: 20mg
- Half-life: ~6 days (SC)
- Reconstitution: 3ml bacteriostatic water → 6.6mg/ml

## Pricing
- One-time: $175 (MSRP $229.97 · list $199.97)
- Subscribe & save: $157.50
- Stack-tier floor (3+ vials in cart): $140
- Crypto checkout (BTC, ETH, USDC, USDT, LTC): -8% across cart
- Free tracked US shipping at $200+ subtotal, otherwise $18 flat

## Stock
- Current: 20 vials

## Pitch
Next-generation triple-receptor agonist (GLP-1 + GIP + glucagon). 20mg per vial for metabolic pathway research.

## Mechanism
Retatrutide is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. In vitro it activates all three receptors with sub-nanomolar potency in cAMP-accumulation assays, with characterized bias profiles distinct from dual-agonist Tirzepatide.

## Common in-vitro applications
### GLP-1/GIP/glucagon receptor signaling
cAMP accumulation + β-arrestin recruitment assays in CHO cells stably expressing each receptor.
Working range: `pM to nM range`

### Adipocyte lipolysis modeling
Comparative lipolysis assays in 3T3-L1 differentiated adipocytes vs Tirzepatide.
Working range: `1 nM to 100 nM`

### Hepatic energy expenditure
Mitochondrial respiration (Seahorse XF) measurements in HepG2 hepatocytes.
Working range: `10 nM to 1 µM`

## Researchers commonly co-treat with
- **Tirzepatide** — Side-by-side dual vs triple agonist comparison in receptor activation panels.
- **Semaglutide** — Single-agonist baseline for receptor-bias and ligand-residency studies.

## Storage and handling
- Lyophilized: −20°C or below, desiccated
- Reconstituted: 2–8°C, use within 30 days
- Light + air: Protect from light and air
- Solubility: Soluble in bacteriostatic water (0.9% benzyl alcohol)

## Selected peer-reviewed citations
- Coskun T, et al. (2022). LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. *Cell Metabolism*.
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. *New England Journal of Medicine*.

## Bundled in research stacks
- [Recomp Elite](https://aurex.bio/stacks/recomp-elite) — $259.97
- [The Flagship — Aurex Elite](https://aurex.bio/stacks/flagship-bundle) — $1,299.97

## Verification
- Independently re-tested at Janoshik Analytical (HPLC-UV at 214 nm + ESI mass spectrometry).
- 100% purity-replacement guarantee: any batch failing an independent retest gets reshipped free.
- Per-batch QR code on the outer kit card resolves to https://aurex.bio/research/batch/[id].

## Compliance
Aurex is a chemical supplier and is **not** a compounding pharmacy or an outsourcing facility as defined under the Federal Food, Drug, and Cosmetic Act. Aurex products are not pharmaceuticals, food additives, or dietary supplements. Aurex does not provide dosage or use guidance — Federal regulations governing research-chemical distribution prohibit it. Distributed strictly for in-vitro laboratory research by qualified researchers 21+. Not for human or veterinary use. Not FDA approved.

---
Wiki: https://aurex.bio/wiki · API: https://aurex.bio/api · Bot: https://t.me/Aurex33bot
Generated 2026-05-04